Table 1.
Baseline demographic and laboratory data for African American participants with APOL1 genotyping in Systolic Blood Pressure Intervention Trial (SPRINT)
| Variable | APOL1 G1+G2 2 risk variants n = 360 |
APOL1 G1+G2 0/1 risk variants n = 2208 |
P value |
|---|---|---|---|
| Randomized to intensive treatment | 190 (52.8) | 1,074 (48.6) | 0.162 |
| Age (yr), mean ± SD | 63.5 ± 9.0 | 64.4 ± 9.0 | 0.053 |
| Female sex | 169 (46.9) | 997 (45.2) | 0.565 |
| Education | 0.105 | ||
| Less than high school | 66 (18.3) | 320 (14.5) | |
| High school | 228 (63.3) | 1,372 (62.1) | |
| College graduate | 46 (12.8) | 332 (15.0) | |
| Graduate degree | 20 (5.6) | 183 (8.3) | |
| Missing | 0 (0.0) | 1 (0.0) | |
| Alcohol consumption | 0.663 | ||
| Nondrinker | 200 (55.6) | 1,203 (54.5) | |
| Light drinker | 72 (20.0) | 415 (18.8) | |
| Moderate drinker | 42 (11.7) | 308 (13.9) | |
| Heavy drinker | 22 (6.1) | 156 (7.1) | |
| Missing | 24 (6.7) | 126 (5.7) | |
| Smoking status | 0.167 | ||
| Never smoker | 169 (46.9) | 950 (43.1) | |
| Former smoker | 105 (29.2) | 754 (34.2) | |
| Current smoker | 86 (23.9) | 501 (22.7) | |
| Pack-yr in smokers, mean ± SD | 16.1 ± 18.9 | 16.2 ± 17.5 | 0.214 |
| Body mass index (kg/m2), mean ± SD | 31.5 ± 6.7 | 30.8 ± 6.3 | 0.044 |
| History of CVD | 60 (16.7) | 359 (16.3) | 0.907 |
| Systolic BP (mm Hg), mean ± SD | 139.4 ± 15.8 | 139.8 ± 16.4 | 0.653 |
| Diastolic BP (mm Hg), mean ± SD | 82.3 ± 12.6 | 81.1 ± 12.4 | 0.081 |
| eGFR (ml/min/1.73 m2), mean ± SD | 73.3 ± 24.6 | 76.8 ± 22.6 | 0.008 |
| eGFR < 60 ml/min/1.73 m2 | 102 (28.4) | 524 (23.8) | 0.069 |
| UACR (mg/g), median (IQR) | 12.2 (6.5−32.8) | 8.7 (5.0−21.5) | <0.001 |
| Albuminuria | <0.001 | ||
| UACR ≤ 30 mg/g | 255 (72.9) | 1,707 (80.3) | |
| UACR >30 to ≤ 300 mg/g | 71 (20.3) | 354 (16.6) | |
| UACR > 300 mg/g | 24 (6.9) | 66 (3.1) | |
| Fasting glucose (mg/dl), mean ± SD | 96.8 ± 13.9 | 97.9 ± 16.0 | 0.213 |
| Total cholesterol (mg/dl), mean ± SD | 195.8 ± 42.3 | 196.2 ± 40.6 | 0.837 |
| HDL cholesterol (mg/dl), mean ± SD | 54.4 ± 13.8 | 55.3 ± 15.2 | 0.280 |
| No. of antihypertensive medications, mean ± SD | 2.1 ± 1.1 | 2.0 ± 1.0 | 0.062 |
| ACEi/ARB use | 202 (56.1) | 1,151 (52.1) | 0.178 |
| Statin use | 123 (34.3) | 744 (33.9) | 0.944 |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate, based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; HDL, high-density lipoprotein; IQR, interquartile range; UACR, urine albumin:creatinine ratio.
Data in parentheses reflect %, unless otherwise noted. Other rows display mean ± SD or median (IQR).